Pathological mechanisms of bortezomib-induced peripheral neuropathy

Shota Yamamoto, Nobuaki Egashira

Research output: Contribution to journalArticlepeer-review

57 Citations (Scopus)


Bortezomib, a first-generation proteasome inhibitor widely used in chemotherapy for hematologic malignancy, has effective anti-cancer activity but often causes severe peripheral neuropathy. Although bortezomib-induced peripheral neuropathy (BIPN) is a dose-limiting toxicity, there are no recommended therapeutics for its prevention or treatment. One of the most critical problems is a lack of knowledge about pathological mechanisms of BIPN. Here, we summarize the known mechanisms of BIPN based on preclinical evidence, including morphological abnormalities, involvement of non-neuronal cells, oxidative stress, and alterations of transcriptional programs in both the peripheral and central nervous systems. Moreover, we describe the necessity of advancing studies that identify the potential efficacy of approved drugs on the basis of pathological mechanisms, as this is a convincing strategy for rapid translation to patients with cancer and BIPN.

Original languageEnglish
Article number888
Pages (from-to)1-14
Number of pages14
JournalInternational journal of molecular sciences
Issue number2
Publication statusPublished - Jan 2 2021

All Science Journal Classification (ASJC) codes

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry


Dive into the research topics of 'Pathological mechanisms of bortezomib-induced peripheral neuropathy'. Together they form a unique fingerprint.

Cite this